替吉奥、顺铂联合多西他赛协同治疗宫颈癌的临床效果

摘要
图/表
参考文献(20)
相关文章 (15)

全文: PDF (597 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的观察替吉奥、顺铂联合多西他赛协同治疗宫颈癌的临床效果，初步探讨其可能的起效机制。方法选择2017年6月~2019年1月湖北省武汉市协和医院收治的宫颈癌患者112例为研究对象，按照随机数字表法分为对照组和观察组，每组56例。对照组给予替吉奥联合顺铂治疗，观察组在对照组基础上加用多西他赛，比较两组的临床疗效，血清肿瘤标志物、Th1/Th2细胞因子含量、免疫功能水平变化，记录用药过程的不良反应。结果观察组疾病控制率、客观缓解率高于对照组，差异有统计学意义（P ＜ 0.05）。治疗后两组癌胚抗原、糖类抗原19-9（CA19-9）、CA125、鳞状上皮细胞癌抗原水平低于治疗前，且观察组低于对照组，差异均有统计学意义（均P < 0.05）。治疗后观察组γ干扰素（IFN-γ）、肿瘤坏死因子-α（TNF-α）、白细胞介素-2（IL-2）水平高于治疗前，IL-4、IL-6、IL-10水平低于治疗前；观察组IFN-γ、TNF-α、IL-2水平高于对照组，IL-4、IL-6、IL-10水平低于对照组，差异均有统计学意义（均P < 0.05）。两组治疗过程中不良反应发生率比较，差异有统计学意义（P ＜ 0.05）。结论多西他赛、替吉奥联合顺铂治疗宫颈癌的临床效果确切，可降低血清肿瘤标志物水平，纠正Th1/Th2细胞免疫失衡状态，且减少不良反应，值得进行临床推广。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	李锦梧1 胡珊2 刘雁云3 许海3

关键词 ：宫颈癌, 多西他赛, 替吉奥, 顺铂, 血清肿瘤标志物, Th1/Th2细胞因子

Abstract：Objective To observe the clinical effect of Tigapine, Cisplatin and Docetaxel in the treatment of cervical cancer and to explore the possible mechanism of action. Methods From June 2017 to January 2019, 112 cases with cervical cancer who admitted to Wuhan Union Hospital of Hubei Province were selected. According to random number table method, they were divided into control group and observation group, with 56 cases in each group. Control group was treated with Tigapine combined with Cisplatin and observation group was treated with Docetaxel on the basis of control group. The clinical efficacy of the two groups, and changes in serum tumor markers, Th1/Th2 cytokine content and immune function level was compared the adverse reactions during medication was recorded. Results The disease control rate and the objective remission rate of observation group were higher than those of control group, and the difference was statistically significant (P < 0.05). After treatment, the levels of carcino-embryonic antigen, carbohydrate antigen 19-9 (CA19-9), CA125 and squamous cell carcinoma antigen in two groups were lower than those before treatment, and observation group was lower than control group, and the differences were statistically significant (all P < 0.05). After treatment, the levels of γ interferon (IFN-γ), tumor necrosis factor-α (TNF-α) and interleukin-2 (IL-2) in observation group were higher than those before treatment, and the levels of IL-4, IL-6 and IL-10 were lower than those before treatment; and the levels of IFN-γ, TNF-α and IL-2 in observation group were higher than those in control group, and the levels of IL-4, IL-6, and IL-10 in observation group were lower than those in control group, with statistically significant differences (all P < 0.05). The incidence of adverse reactions during treatment in two groups was statistically significant (P < 0.05). Conclusion The clinical effect of Docetaxel and Tigapine combined with Cisplatin in the treatment of advanced cervical cancer is definite, which is conducive to reducing the level of serum tumor markers, correcting the immune imbalance of Th1/Th2 cells and reducing adverse reactions, which is worthy of clinical promotion.

Key words： Cervical cancer Docetaxel Tigapine Cisplatin Serum tumor markers Th1/Th2 cytokines

基金资助:湖北省自然科学基金项目（2018CFC808）；
湖北省卫生健康委员会科研项目（WJ2019M254）。

通讯作者: 刘雁云(1975-)，女，博士，副教授；研究方向：妇科常见临床疾病治疗。

引用本文:

李锦梧1 胡珊2 刘雁云3 许海3. 替吉奥、顺铂联合多西他赛协同治疗宫颈癌的临床效果[J]. 中国医药导报, 2020, 17(14): 94-97,117.
LI Jinwu1 HU Shan2 LIU Yanyun3 XU Hai3. Clinical effect of Tigapine and Cisplatin combined with Docetaxel in the treatment of cervical cancer. 中国医药导报, 2020, 17(14): 94-97,117.

链接本文:

http://www.yiyaodaobao.com.cn/CN/ 或 http://www.yiyaodaobao.com.cn/CN/Y2020/V17/I14/94

[1] Onal C，Yildirim BA，Guler OC，et al. The Utility of Pretreatment and Posttreatment Lymphopenia in Cervical Squamous Cell Carcinoma Patients Treated With Definitive Chemoradiotherapy [J]. Int J Gynecol Cancer，2018， 28（8）：1553-1559.
[2] Khanal S，Shumway BS，Zahin M，et al. Viral DNA integration and methylation of human papillomavirus type 16 in high-grade oral epithelial dysplasia and head and neck squamous cell carcinoma [J]. Oncotarget，2018，9（54）：30419-30433.
[3] 文丽芳，丁洁.加味人参养荣汤联合化疗对宫颈癌患者血清肿瘤标志物，Th1/Th2型细胞因子表达水平的影响[J].中国实验方剂学杂志，2019，25（5）：68-72.
[4] 郑莉花，金延泽，曾婕，等.卡铂联合紫杉醇对宫颈癌患者Th1/Th2类细胞因子的影响及疗效分析[J].肿瘤药学，2018，8（6）：880-884.
[5] 董亚楠，鲍英丽，王圆媛.金龙胶囊联合DP方案治疗中晚期宫颈癌的疗效观察[J].现代药物与临床，2018，33（12）：3250-3253.
[6] 彭文盈，梁实，赵玉梅.多西他赛联合替吉奥胶囊对中晚期宫颈癌患者血清肿瘤标记物及免疫水平的影响[J].中国计划生育学杂志，2018，26（6）：460-464.
[7] 魏丽惠.妇产科 [M].北京：中国医药科技出版社，2014：69.
[8] 陈龙邦.现代肿瘤循证诊疗手册[M].郑州：郑州大学出版社，2007：517.
[9] US Preventive Services Task Force，Curry SJ，Krist AH，et al. Screening for Cervical Cancer：US Preventive Services Task Force Recommendation Statement [J]. JAMA，2018， 320（7）：674-686.
[10] 张利元，李燕，祝绚，等.高危型人乳头瘤病毒感染与女性生殖道常见病原菌和宫颈病变的关系[J].现代生物医学进展，2019，19（9）：1753-1757.
[11] Musa J， Achenbach CJ，O′Dwyer LC，et al. Effect of cervical cancer education and provider recommendation for screening on screening rates：A systematic review and meta-analysis [J]. PLoS One，2017，12（9）：e0183924.
[12] 刘宏峰，张彩虹，赵培庆.TIPE2负调控白细胞介素-6影响宫颈癌耐药细胞株Siha对顺铂化疗敏感性的机制研究[J].中国妇幼保健，2019，34（9）：2123-2125.
[13] 李娜，李辉，马春雨，等.紫杉醇联合顺铂新辅助化疗与同步放化疗在局部晚期宫颈癌中的疗效评价[J].中国妇产科临床杂志，2019，20（3）：227-229.
[14] 杨吉帆，任洪波，李春梅，等.替吉奥胶囊+康艾注射液+调强放疗对晚期宫颈癌病灶内细胞恶性生物学进程的影响[J].海南医学院学报，2017，23（17）：2408-2411.
[15] 刘剑.多西他赛联合替吉奥治疗蒽环类耐药的晚期乳腺癌临床观察[J].肿瘤基础与临床，2019，32（1）：49-50.
[16] 陆绍华，章秀梅，陈寅，等.康艾注射液和替吉奥胶囊联合调强放疗治疗晚期宫颈癌患者的临床观察[J].中国药师，2019，22（6）：1093-1095.
[17] 杨德红.晚期宫颈癌介入与放射治疗的疗效及对Th1/Th2细胞因子水平分析[J].基因组学与应用生物学，2018， 37（2）：589-595.
[18] 季菲，何艳，杨丽，等.宫颈癌患者Th1/Th2细胞因子的表达及其预后意义[J].重庆医学，2018，47（33）：4229-4233.
[19] 刘璐，程桂丽，刘世兰，等.宫颈癌患者血清Th1、Th2细胞因子表达水平及意义[J].癌症进展，2017，15（2）：156-158.
[20] 杨华，赵璐，陈叙.Th1/Th2平衡调控对妇产科疾病影响的研究进展[J].国际妇产科学杂志，2018，45（5）：579-581.